Pharmaceutical manufacturing
Why the pharmaceutical batch record has to be written during the run
In a small pharmaceutical plant the batch record is often written after the run. Materials, steps, in-process checks, and yield are reconstructed when the batch is already closed. A discrepancy found then is an explanation. The same fact during the batch is still something the plant can hold or correct.
Oral solid, liquid, topical, and packaging rooms share the pattern. The master on the floor is not always the one quality released. The change was a message. The batch used the old one. Nobody sees that until the record is assembled.
What has to be true before release
- Eligible material before the start. Quarantine, hold, and released stock are not the same quantity.
- The master with the batch. The lots that were actually used stay with the formula the floor ran.
- Checks while the batch is open. A missing in-process result should be visible before the batch is closed and released anyway.
- Genealogy both ways, from a component lot to the finished batches, and from a finished lot back to shipment.
- Actual cost against the standard, including yield loss and rework, before the next cycle is released on a number that never saw the rework.
In-process visibility is this idea in general. In a pharmaceutical plant it is the difference between a blank check found at release and a blank check found while the batch can still be held. Lot genealogy is the list a customer asks for after a component lot needs to be named.
Where the cost hides
Rework that happened mid-batch never lands on the batch cost. The standard still looks fine. The next cycle is released on that standard. Yield loss and rework shrink when the reason is on the open batch, not in a report after the material is gone.
MFGMAX Pharma keeps materials, the running batch, in-process checks, lot genealogy, and batch cost on the same record. Accounting can stay in QuickBooks. This does not replace your quality system, a validation, or an FDA approval.
Questions plants ask
When should a pharmaceutical batch record be written?
While the batch is running. Materials, steps, in-process checks, and yield that are reconstructed after the batch is closed explain a discrepancy. The same fact during the batch is still something the plant can hold or correct.
What should be visible before the batch starts?
Which material lot is eligible. Quarantine, hold, and released stock are not one quantity, and a component lot that is short-dated should be visible before it is issued.
Does this replace a quality system or an FDA approval?
No. This does not replace your quality system, a validation, or an FDA approval. It keeps materials, the running batch, in-process checks, lot genealogy, and batch cost on the same record.
| Written after closeout | Written during the run | |
|---|---|---|
| Checks | Blanks found when someone wants to release | A missing result is on the open batch |
| Genealogy | A search after the customer asks | Component lots already tied to the finished batch |
| Cost | The standard still looks fine | Yield loss and rework sit on the batch |